Doxycycline continues to show promise for STI prevention, but not in cisgender women

SEATTLE — Studies continue to show that taking doxycycline after having unprotected sex can prevent STIs in transgender women and men who have sex with men. What has been unclear is whether it also works for cisgender women.
On Monday, researchers at the Conference on Retroviruses and Opportunistic Infections presented the first major evidence that it may not.
Specifically, a randomized trial conducted in Kenya found that an intervention of doxycycline postexposure prophylaxis — called doxy-PEP — did not significantly reduce STIs among cisgender women compared with testing and

SEATTLE — Studies continue to show that taking doxycycline after having unprotected sex can prevent STIs in transgender women and men who have sex with men. What has been unclear is whether it also works for cisgender women.
On Monday, researchers at the Conference on Retroviruses and Opportunistic Infections presented the first major evidence that it may not.
Specifically, a randomized trial conducted in Kenya found that an intervention of doxycycline postexposure prophylaxis — called doxy-PEP — did not significantly reduce STIs among cisgender women compared with testing and